- Fondo de Protección
  Fondo de protección de 1.000 BTC para proteger tus activos
- Carreras
  Únete a WEEX y construye el futuro
- Zona WXT
  Tasas de comisiones y airdrops exclusivos
- Centro de anuncios
  Mantente al día con las actualizaciones de WEEX
- Trader Élite
  Comparte estrategias y gana recompensas
- Wiki Cripto
  Domina el trading con guías sencillas de seguir
- Afiliado
  Consigue ventajas exclusivas y comisiones atractivas
- Noticias cripto
  Mantente al tanto de las últimas tendencias cripto
- Verificador de Contactos
  Verifica los canales que usas
- Ventajas VIP
  Hazte VIP de WEEX hoy
- Calendario de eventos
  Descubre los eventos de WEEX en todo el mundo
Comprar cripto
- header.nav.buy
  header.nav.buy_desc
- Comercio P2P
  Compra cripto sin comisiones
Mercados
Futuros
- Futuros USDT-M
  Futuros perpetuos liquidados en USDT
- Trading demo
  Futuros USDT-M demo
- Acerca de los futuros
  Opera con confianza
- Clasific.
  Clas. act. y ant.
Spot
Copy trading
WE-Launch

Escanear para descargar
Más opciones

US Biopharmaceutical Company Liminatus Pharma Plans to Raise $500 Million to Invest in BNB

By: theblockbeats.news|2025/07/28 12:12:26

BlockBeats News, July 28th, According to a report by businessinsider, Clinical-stage biopharmaceutical company Liminatus Pharma, Inc. (NASDAQ: LIMN) today announced plans to strategically expand into the cryptocurrency and blockchain space.

The company plans to establish a subsidiary named "American BNB Strategy" to lead its digital asset investment and management plan. Through this platform, Liminatus plans to gradually raise and deploy up to $500 million in funds, with the goal of strategically long-term investing in BNB.

Liminatus emphasized that while the company remains fully committed to its core business - advancing cancer treatments and pancreatic cancer diagnostic technologies, expanding into the digital asset space is seen as a necessary step to support long-term growth and enhance shareholder value.

Liminatus is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer patients. The company is advancing a series of novel therapies targeting cancer antigens and tumor-specific immune responses.

WEEX se roba el Show en BlockchainRIO 2025